Stock A334970 PRESTIGE BIOLOGICS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Prestige Biologics Co., Ltd.

Equities

A334970

KR7334970001

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 18:00:00 2024-05-22 EDT 		5-day change 1st Jan Change
4,110 KRW -1.67% Intraday chart for Prestige Biologics Co., Ltd. -0.48% -6.59%
2023 Prestige Biologics Co., Ltd. announced that it has received KRW 45.5 billion in funding from Octava Fund Limited CI
2023 Prestige Biologics Co., Ltd. announced that it expects to receive KRW 45.5 billion in funding from Octava Fund Limited CI

Valuation

Fiscal Period: Juni 2021 2022 2023
Capitalization 1 769,464 206,789 272,542
Enterprise Value (EV) 1 810,801 310,025 387,122
P/E ratio -18.4 x -4.55 x -6.63 x
Yield - - -
Capitalization / Revenue 238,457,616 x 13,284,923,921 x 156,110,072 x
EV / Revenue 251,267,875 x 19,917,188,831 x 221,741,268 x
EV / EBITDA -35.4 x -10.8 x -12.2 x
EV / FCF -6.38 x -3.16 x -
FCF Yield -15.7% -31.7% -
Price to Book 7.2 x 2.27 x 2.73 x
Nbr of stocks (in thousands) 47,206 47,320 61,108
Reference price 2 16,300 4,370 4,460
Announcement Date 3/1/22 3/1/23 8/29/23
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Juni 2020 2021 2022 2023
Net sales - 3,227 15.57 1,746
EBITDA 1 -19,499 -22,916 -28,693 -31,629
EBIT 1 -22,601 -26,837 -36,631 -40,043
Operating Margin - -831.68% -235,333.31% -2,293.61%
Earnings before Tax (EBT) 1 -31,033 -39,378 -49,718 -39,442
Net income 1 -31,033 -39,378 -49,718 -39,442
Net margin - -1,220.33% -319,407.01% -2,259.19%
EPS 2 -876.0 -886.0 -960.7 -672.4
Free Cash Flow 1 -4,038 -127,117 -98,250 -
FCF margin - -3,939.36% -631,195.53% -
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 3/1/21 3/1/22 3/1/23 8/29/23
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: June 2020 2021 2022 2023
Net Debt 1 23,429 41,337 103,236 114,581
Net Cash position 1 - - - -
Leverage (Debt/EBITDA) -1.202 x -1.804 x -3.598 x -3.623 x
Free Cash Flow 1 -4,038 -127,117 -98,250 -
ROE (net income / shareholders' equity) -226% -74.7% -44.3% -
ROA (Net income/ Total Assets) -23.1% -13.1% -9.85% -
Assets 1 134,382 301,680 504,735 -
Book Value Per Share 2 -39.30 2,263 1,925 1,633
Cash Flow per Share 2 119.0 779.0 252.0 744.0
Capex 1 2,969 97,392 84,642 35,435
Capex / Sales - 3,018.19% 543,775.64% 2,029.71%
Announcement Date 3/1/21 3/1/22 3/1/23 8/29/23
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Biopharmaceuticals

1st Jan change Capi.
PRESTIGE BIOLOGICS CO., LTD. Stock Prestige Biologics Co., Ltd.
-6.59% 188M
CSL LIMITED Stock CSL Limited
-2.17% 89.22B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 40.49B
BIOGEN INC. Stock Biogen Inc.
-15.73% 32.79B
UCB Stock UCB
+64.13% 26.23B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-21.28% 14.52B
INCYTE CORPORATION Stock Incyte Corporation
-8.50% 13.09B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-44.07% 11.6B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-13.06% 11.5B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+4.94% 8.82B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. A334970 Stock
  4. Financials Prestige Biologics Co., Ltd.